Medicinal products — List of marketing authorisations granted by the EEA EFTA States for the second half of 2012
Date: 2014-10-09
Institutions: Standing Committee of the EFTA States
Subjects: EFTA countries, free movement of goods, market approval, medicinal product








C_2014356EN.01003701.xml










9.10.2014   


EN


Official Journal of the European Union


C 356/37





Medicinal products — List of marketing authorisations granted by the EEA EFTA States for the second half of 2012
2014/C 356/08

Subcommittee I on the free movement of goods


To be noted by the EEA Joint Committee

With reference to EEA Joint Committee Decision No 74/1999 of 28 May 1999, the EEA Joint Committee is invited to note the following lists concerning marketing authorisations for medicinal products for the period 1 July-31 December 2012, at their meeting on 8 November 2013:







Annex I



List of new marketing authorisations





Annex II



List of renewed marketing authorisations





Annex III



List of extended marketing authorisations





Annex IV



List of withdrawn marketing authorisations





Annex V



List of suspended marketing authorisations






ANNEX I
List of new marketing authorisations
The following marketing authorisations have been granted in the EEA EFTA States during the period 1 July- 31 December 2012:








EU-Number


Product


Country


Date of authorisation




EU/1/11/685/001-005


Ibandronic acid Sandoz


Norway


31.7.2012




EU/1/11/719/001-062


Telmisartan Teva Pharma


Liechtenstein


31.12.2012




EU/1/11/744/001-002


Topotecan Eagle


Norway


30.8.2012




EU/1/11/747/001


Colobreathe


Norway


11.7.2012




EU/1/11/748/001-006


Docetaxel Mylan


Norway


17.12.2012




EU/1/12/762/001-018


Capecitabine Accord


Norway


13.8.2012




EU/1/12/768/001


Riluzole Zentiva


Norway


16.8.2012




EU/1/12/769/001-003


Docetaxel Accord


Norway


13.8.2012




EU/1/12/771/001-006


Zoledronic Acid Teva


Iceland


10.9.2012




EU/1/12/771/001-006


Zoledronic acid Teva


Norway


12.10.2012




EU/1/12/772/001-004


Zoledronic acid Teva Pharma


Iceland


10.9.2012




EU/1/12/772/001-004


Zoledronic acid Teva Pharma


Norway


10.10.2012




EU/1/12/773/001-003


Jakavi


Liechtenstein


31.8.2012




EU/1/12/773/001-003


Jakavi


Norway


5.9.2012




EU/1/12/773/001-003


Jakavi


Iceland


19.9.2012




EU/1/12/774/001-002


Rienso


Norway


14.8.2012




EU/1/12/774/001-002


Rienso


Iceland


20.7.2012




EU/1/12/774/001-002


Rienso


Liechtenstein


31.12.2012




EU/1/12/775/001


NovoThirteen


Iceland


17.9.2012




EU/1/12/775/001


Novo Thirteen


Norway


19.9.2012




EU/1/12/775/001


Novo Thirteen


Liechtenstein


31.10.2012




EU/1/12/776/001-016


Fycompa


Norway


27.8.2012




EU/1/12/776/001-016


Fycompa


Liechtenstein


31.8.2012




EU/1/12/776/001-016


Fycompa


Iceland


11.9.2012




EU/1/12/777/001-006


Inlyta


Iceland


14.9.2012




EU/1/12/777/001-006


Inlyta


Norway


21.9.2012




EU/1/12/777/001-006


Inlyta


Liechtenstein


31.10.2012




EU/1/12/778/001-003


Eklira Genuair


Iceland


13.8.2012




EU/1/12/778/001-003


Eklira Genuair


Norway


15.8.2012




EU/1/12/778/001-003


Eklira Genuair


Liechtenstein


31.8.2012




EU/1/12/779/001-006


Zoledronic acid medac


Norway


15.8.2012




EU/1/12/779/001-006


Zoledronic acid medac


Iceland


27.8.2012




EU/1/12/779/001-006


Zoledronic acid medac


Liechtenstein


31.8.2012




EU/1/12/780/001-028


Jentadueto


Norway


31.7.2012




EU/1/12/780/001-028


Jentadueto


Liechtenstein


31.8.2012




EU/1/12/780/001-028


Jentadueto


Iceland


17.8.2012




EU/1/12/781/001-003


Bretaris Genuair


Iceland


13.8.2012




EU/1/12/781/001-003


Bretaris Genuair


Norway


15.8.2012




EU/1/12/781/001-003


Bretaris Genuair


Liechtenstein


31.8.2012




EU/1/12/782/001-002


Kalydeco


Norway


6.8.2012




EU/1/12/782/001-002


Kalydeco


Iceland


21.8.2012




EU/1/12/782/001-002


Kalydeco


Liechtenstein


31.8.2012




EU/1/12/783/001-003


Zyclara


Liechtenstein


31.8.2012




EU/1/12/783/001-003


Zyclara


Iceland


12.9.2012




EU/1/12/783/001-003


Zyclara


Norway


10.10.2012




EU/1/12/784/001


Cuprymina


Iceland


7.9.2012




EU/1/12/784/001


Cuprymina


Norway


25.9.2012




EU/1/12/784/001


Cuprymina


Liechtenstein


31.10.2012




EU/1/12/785/001


Zinforo


Liechtenstein


31.8.2012




EU/1/12/785/001


Zinforo


Iceland


6.9.2012




EU/1/12/785/001


Zinforo


Norway


17.9.2012




EU/1/12/786/001-003


Zoledronic acid Mylan


Liechtenstein


31.8.2012




EU/1/12/786/001-003


Zoledronic acid Mylan


Iceland


4.9.2012




EU/1/12/786/001-003


Zoledronic acid Mylan


Norway


12.10.2012




EU/1/12/787/001


Revestive


Iceland


14.9.2012




EU/1/12/787/001


Revestive


Norway


26.9.2012




EU/1/12/787/001


Revestive


Liechtenstein


31.10.2012




EU/1/12/788/001-006


Seebri Breezhaler


Iceland


16.10.2012




EU/1/12/788/001-006


Seebri Breezhaler


Norway


17.10.2012




EU/1/12/789/001-006


Enurev Breezhaler


Iceland


17.10.2012




EU/1/12/789/001-006


Enurev Breezhaler


Norway


29.10.2012




EU/1/12/790/001-006


Tovanor Breezhaler


Iceland


17.10.2012




EU/1/12/790/001-006


Tovanor Breezhaler


Norway


29.10.2012




EU/1/12/791/001


Glybera


Iceland


15.11.2012




EU/1/12/791/001


Glybera


Norway


6.12.2012




EU/1/12/792/001


Dacogen


Iceland


15.10.2012




EU/1/12/792/001


Dacogen


Norway


17.10.2012




EU/1/12/792/001


Dacogen


Liechtenstein


31.10.2012




EU/1/12/793/001-004


Xalkori


Iceland


8.11.2012




EU/1/12/793/001-004


Xalkori


Norway


14.11.2012




EU/1/12/793/001-004


Xalkori


Liechtenstein


31.12.2012




EU/1/12/794/001


Adcetris


Norway


10.12.2012




EU/1/12/794/001


Adectris


Liechtenstein


31.12.2012




EU/1/12/795/001-010


Forxiga


Norway


6.12.2012




EU/1/12/795/001-010


Forxiga


Iceland


7.12.2012




EU/1/12/796/001-002


Picato


Norway


27.11.2012




EU/1/12/796/001-002


Picato


Iceland


7.12.2012




EU/1/12/796/001-002


Picato


Liechtenstein


31.12.2012




EU/1/12/797/001-002


Eylea


Norway


6.12.2012




EU/1/12/797/001-002


Eylea


Iceland


13.12.2012




EU/1/12/798/001-004


Ibandronic acid Accord


Norway


12.12.2012




EU/1/12/798/001-004


Ibandronic acid Accord


Iceland


10.12.2012




EU/1/12/798/001-004


Ibandronic acid Accord


Liechtenstein


31.12.2012




EU/1/12/799/001-029


Memantine Merz


Iceland


12.12.2012




EU/1/12/799/001-029


Memantine Merz


Liechtenstein


31.12.2012




EU/1/12/800/001-004


Zoledronic Acid Hospira


Iceland


7.12.2012




EU/1/12/800/001-004


Zoledronic acid Hospira


Norway


17.12.2012




EU/1/12/800/001-004


Zoledronic acid Hospira


Liechtenstein


31.12.2012




EU/1/12/801/001-004


Constella


Iceland


13.12.2012




EU/1/12/801/001-004


Constella


Liechtenstein


31.12.2012




EU/1/12/801/001-004


Constella


Norway


17.12.2012




EU/1/12/802/001-042


Capecitabine medac


Norway


13.12.2012




EU/1/12/802/001-042


Capecitabine medac


Iceland


18.12.2012




EU/1/12/802/001-042


Capecitabine medac


Liechtenstein


31.12.2012




EU/2/09/099/001-006


Suvaxyn PCV


Iceland


8.11.2012




EU/2/11/122/001-003


Bluevac BTV8


Norway


18.7.2012




EU/2/12/138/001-003


RevitaCAM


Norway


19.9.2012




EU/2/12/140/001-008


Poulvac E. Coli


Iceland


23.7.2012




EU/2/12/141/001-009


Porcilis ColiClos


Iceland


5.7.2012




EU/2/12/141/001-009


Porcilis ColiClos


Norway


31.7.2012




EU/2/12/141/001-009


Porcilis ColiClos


Liechtenstein


31.8.2012




EU/2/12/142/001-006


Cardalis 2,5/20 mg


Iceland


20.8.2012




EU/2/12/143/001-005


Nobivac L4


Iceland


20.8.2012




EU/2/12/143/001-005


Nobivac L4


Norway


28.8.2012




EU/2/12/143/001-005


Nobivac L4


Liechtenstein


31.8.2012







ANNEX II
List of renewed marketing authorisations
The following marketing authorisations have been renewed in the EEA EFTA States during the period 1 July- 31 December 2012:








EU-Number


Product


Country


Date of authorisation




EU/1/01/187/001


DepoCyte


Norway


13.8.2012




EU/1/01/197/001-005


Foscan


Norway


7.9.2012




EU/1/02/222/001-005


Tamiflu


Norway


21.8.2012




EU/1/02/223/001-003


Evra


Iceland


5.7.2012




EU/1/02/223/001-003


Evra


Norway


27.8.2012




EU/1/02/223/001-003


Evra


Liechtenstein


31.8.2012




EU/1/02/224/001-005


Ambirix


Iceland


21.8.2012




EU/1/02/224/001-005


Ambirix


Norway


27.8.2012




EU/1/02/224/001-005


Ambirix


Liechtenstein


31.8.2012




EU/1/02/226/001


InductOs


Norway


2.8.2012




EU/1/02/226/001


InductOs


Iceland


14.8.2012




EU/1/02/237/001-009


Cialis


Norway


11.10.2012




EU/1/02/237/001-009


Cialis


Iceland


17.10.2012




EU/1/02/237/001-009


Cialis


Liechtenstein


31.10.2012




EU/1/02/238/001


Zavesca


Iceland


22.10.2012




EU/1/02/238/001


Zavesca


Norway


29.10.2012




EU/1/02/238/001


Zavesca


Liechtenstein


31.10.2012




EU/1/05/314/001


Kepivance


Norway


11.9.2012




EU/1/06/339/001-002


Preotact


Norway


28.8.2012




EU/1/06/367/001-012


Diacomit


Norway


12.12.2012




EU/1/06/367/001-012


Diacomit


Iceland


13.12.2012




EU/1/06/367/001-012


Diacomit


Liechtenstein


31.12.2012




EU/1/06/371/001-039


Dafiro


Norway


26.9.2012




EU/1/06/376/001-039


Irbesartan Zentiva


Iceland


28.9.2012




EU/1/07/393/001


Soliris


Iceland


5.7.2012




EU/1/07/393/001


Soliris


Norway


13.8.2012




EU/1/07/394/001-009


Optaflu


Iceland


8.11.2012




EU/1/07/395/001-095


Invega


Iceland


31.8.2012




EU/1/07/395/001-095


Invega


Norway


11.9.2012




EU/1/07/397/001-004


Siklos


Iceland


23.7.2012




EU/1/07/397/001-004


Siklos


Norway


9.8.2012




EU/1/07/398/001-014


Optimark


Iceland


5.7.2012




EU/1/07/398/001-014


Optimark


Liechtenstein


31.8.2012




EU/1/07/401/007-016


alli


Iceland


20.7.2012




EU/1/07/401/007-016


alli


Liechtenstein


31.8.2012




EU/1/07/402/001


Increlex


Iceland


29.8.2012




EU/1/07/402/001


Increlex


Liechtenstein


31.8.2012




EU/1/07/402/001


Increlex


Norway


3.9.2012




EU/1/07/403/001


Atriance


Iceland


20.7.2012




EU/1/07/403/001


Atriance


Norway


7.8.2012




EU/1/07/403/001


Atriance


Liechtenstein


31.8.2012




EU/1/07/404/001-008


Flebogamma DIF


Iceland


11.9.2012




EU/1/07/404/001-008


Flebogamma DIF


Norway


12.10.2012




EU/1/07/405/001-040


Rasilez


Liechtenstein


31.8.2012




EU/1/07/405/001-040


Rasilez


Iceland


19.9.2012




EU/1/07/405/001-040


Rasilez


Norway


10.10.2012




EU/1/07/409/001-040


Riprazo


Iceland


12.9.2012




EU/1/07/409/001-040


Riprazo


Norway


10.10.2012




EU/1/07/409/001-040


Riprazo


Liechtenstein


31.8.2012




EU/1/07/410/001-052


Binocrit


Norway


27.8.2012




EU/1/07/410/001-052


Binocrit


Iceland


20.7.2012




EU/1/07/410/001-052


Binocrit


Liechtenstein


31.8.2012




EU/1/07/411/001-052


Epoetin alfa Hexal


Iceland


19.7.2012




EU/1/07/411/001-052


Epoetin alfa Hexal


Norway


27.8.2012




EU/1/07/411/001-052


Epoetin alfa Hexal


Liechtenstein


31.8.2012




EU/1/07/412/001-052


Abseamed


Iceland


20.7.2012




EU/1/07/412/001-052


Abseamed


Norway


27.8.2012




EU/1/07/413/001-003


Gliolan


Iceland


7.9.2012




EU/1/07/413/001-003


Gliolan


Norway


15.10.2012




EU/1/07/413/001-003


Gliolan


Liechtenstein


31.10.2012




EU/1/07/414/001-010, 018


Galvus


Iceland


17.8.2012




EU/1/07/414/001-010, 018


Galvus


Norway


31.7.2012




EU/1/07/415/001-056


Zalasta


Norway


24.8.2012




EU/1/07/415/001-056


Zalasta


Iceland


25.8.2012




EU/1/07/415/001-056


Zalasta


Liechtenstein


31.8.2012




EU/1/07/416/002


Ecalta


Iceland


3.9.2012




EU/1/07/416/002


Ecalta


Liechtenstein


31.8.2012




EU/1/07/416/002


Ecalta


Norway


26.9.2012




EU/1/07/417/001-002


Yondelis


Iceland


28.8.2012




EU/1/07/417/001-002


Yondelis


Liechtenstein


31.8.2012




EU/1/07/417/001-002


Yondelis


Norway


17.9.2012




EU/1/07/418/001-010


Celsentri


Liechtenstein


31.8.2012




EU/1/07/418/001-010


Celsentri


Iceland


12.9.2012




EU/1/07/418/001-010


Celsentri


Norway


18.9.2012




EU/1/07/419/001-012


Cervarix


Iceland


12.10.2012




EU/1/07/419/001-012


Cervarix


Norway


12.10.2012




EU/1/07/419/001-012


Cervarix


Liechtenstein


31.10.2012




EU/1/07/420/001-002


Cyanokit


Iceland


14.8.2012




EU/1/07/420/001-002


Cyanokit


Norway


17.8.2012




EU/1/07/420/001-002


Cyanokit


Liechtenstein


31.8.2012




EU/1/07/421/001-009


Glubrava


Iceland


12.10.2012




EU/1/07/421/001-009


Glubrava


Norway


12.10.2012




EU/1/07/421/001-009


Glubrava


Liechtenstein


31.10.2012




EU/1/07/422/001-012


Tasigna


Norway


24.10.2012




EU/1/07/422/001-012


Tasigna


Liechtenstein


31.10.2012




EU/1/07/422/001-012


Tasigna


Iceland


6.12.2012




EU/1/07/424/001


Torisel


Iceland


12.10.2012




EU/1/07/424/001


Torisel


Norway


22.10.2012




EU/1/07/424/001


Torisel


Liechtenstein


31.10.2012




EU/1/07/425/001-018


Eucreas


Norway


31.7.2012




EU/1/07/425/001-018


Eucreas


Iceland


21.8.2012




EU/1/07/425/001-018


Eucreas


Liechtenstein


31.8.2012




EU/1/07/426/001-011


Olanzapine Neopharma


Iceland


17.10.2012




EU/1/07/426/001-011


Olanzapine Neopharma


Norway


24.10.2012




EU/1/07/426/001-011


Olanzapine Neopharma


Liechtenstein


31.10.2012




EU/1/07/427/001-057


Olanzapine Teva


Norway


6.12.2012




EU/1/07/427/001-057


Olanzapine Teva


Iceland


7.12.2012




EU/1/07/427/001-057


Olanzapine Teva


Liechtenstein


31.12.2012




EU/1/07/430/001-002


Atripla


Norway


26.9.2012




EU/1/07/430/001-002


Atripla


Iceland


12.10.2012




EU/1/07/431/001-025


Retacrit


Iceland


7.12.2012




EU/1/07/431/001-025


Retacrit


Norway


17.12.2012




EU/1/07/431/001-025


Retacrit


Liechtenstein


31.12.2012




EU/1/07/432/001-022


Silapo


Iceland


22.8.2012




EU/1/07/432/001-022


Silapo


Norway


24.8.2012




EU/1/07/432/001-022


Silapo


Liechtenstein


31.8.2012




EU/1/07/433/001


Nevanac


Norway


15.10.2012




EU/1/07/433/001


Nevanac


Liechtenstein


31.10.2012




EU/1/07/435/001-018


Tesavel


Iceland


15.10.2012




EU/1/07/435/001-018


Tesavel


Norway


15.10.2012




EU/1/07/437/001-004


IVEMEND


Iceland


7.12.2012




EU/1/07/437/003-004


IVEMEND


Norway


6.12.2012




EU/1/07/437/003-004


IVEMEND


Liechtenstein


31.12.2012




EU/1/07/438/001-006


Myfenax


Iceland


12.12.2012




EU/1/07/438/006


Myfenax


Norway


13.12.2012




EU/1/07/439/001-006


Mycophenolate mofetil Teva


Iceland


12.12.2012




EU/1/07/439/001-006


Mycophenolate mofetil Teva


Norway


17.12.2012




EU/1/08/468/001-002


INTELENCE


Iceland


16.8.2012




EU/1/08/468/001-002


INTELENCE


Norway


27.8.2012




EU/1/08/468/001-002


INTELENCE


Liechtenstein


31.8.2012




EU/1/11/710/001-007


Votubia


Norway


16.8.2012




EU/1/11/710/001-007


Votubia


Iceland


25.8.2012




EU/1/11/710/001-007


Votubia


Liechtenstein


31.8.2012




EU/1/97/047/004-007


BeneFIX


Iceland


16.8.2012




EU/1/97/047/004-007


BeneFIX


Norway


24.8.2012




EU/1/97/047/004-007


BeneFIX


Liechtenstein


31.8.2012




EU/2/02/032/001-002


Vaxxitek HVT + IBD


Iceland


23.7.2012




EU/2/02/032/001-002


Vaxxitek HVT + IBD


Liechtenstein


31.8.2012




EU/2/02/034/001


Nobivac Bb


Iceland


18.9.2012




EU/2/02/034/001


Nobivac Bb


Norway


23.10.2012




EU/2/02/034/001


Nobivac Bb


Liechtenstein


31.10.2012




EU/2/07/072/001-004


Suprelorin


Norway


31.7.2012




EU/2/07/072/001-004


Suprelorin


Liechtenstein


31.8.2012




EU/2/07/074/001-006


Prilactone


Liechtenstein


31.8.2012




EU/2/07/077/001-005


Meloxivet


Iceland


6.12.2012




EU/2/07/077/001-005


Meloxivet


Liechtenstein


31.10.2012







ANNEX III
List of extended marketing authorisations
The following marketing authorisations have been extended in the EEA EFTA States during the period 1 July- 31 December 2012:








EU-Number


Product


Country


Date of authorisation




EU/1/01/200/003-009


Viread


Iceland


18.12.2012




EU/1/04/274/001-002


Velcade


Norway


18.10.2012




EU/1/04/306/002-003


Aloxi


Norway


19.11.2012




EU/1/06/368/169-174


Insulin Human Winthrop


Liechtenstein


31.8.2012




EU/1/06/376/034, 036-039


Irbesartan Zentiva


Liechtenstein


31.10.2012




EU/1/06/376/034, 036-039


Irbesartan Zentiva


Norway


30.8.2012




EU/1/06/377/029-034


Irbesartan HCT Zentiva


Liechtenstein


31.8.2012




EU/1/06/377/029-034


Irbesartan HCT Zentiva


Norway


12.11.2012




EU/1/06/380/006


Prezista


Iceland


14.11.2012




EU/1/06/380/006


Prezista


Norway


24.10.2012




EU/1/07/389/004-009


Orencia


Liechtenstein


31.10.2012




EU/1/07/389/004-009


Orencia


Norway


13.11.2012




EU/1/07/389/004-009


Orencia


Iceland


19.10.2012




EU/1/07/391/005-006


Revlimid


Norway


25.9.2012




EU/1/07/391/005-006


Revlimid


Iceland


11.10.2012




EU/1/07/440/007


Tyverb


Liechtenstein


31.8.2012




EU/1/07/440/007


Tyverb


Norway


31.7.2012




EU/1/09/514/021-023


Zebinix


Liechtenstein


31.8.2012




EU/1/09/514/021-023


Zebinix


Iceland


3.9.2012




EU/1/09/514/021-023


Zebinix


Norway


25.9.2012




EU/1/10/616/025-036


Temozolomide HEXAL


Liechtenstein


31.8.2012




EU/1/10/617/025-036


Temozolomide Sandoz


Liechtenstein


31.8.2012




EU/1/11/691/006-013


Eliquis


Iceland


11.12.2012




EU/1/11/691/006-013


Eliquis


Norway


19.12.2012




EU/1/11/712/029-040


Levetiracetam Accord


Liechtenstein


31.10.2012




EU/1/11/731/013-014


Komboglyze


Liechtenstein


31.10.2012




EU/1/11/731/013-014


Komboglyze


Norway


24.9.2012




EU/1/11/734/012-018


Edarbi


Liechtenstein


31.8.2012




EU/1/11/735/012-018


Ipreziv


Liechtenstein


31.8.2012




EU/1/12/752/002


Vepacel


Liechtenstein


31.10.2012




EU/1/12/765/007-009


Sabervel


Liechtenstein


31.12.2012




EU/1/97/030/196-201


Insuman


Liechtenstein


31.8.2012




EU/1/97/047/008


BeneFIX


Liechtenstein


31.8.2012




EU/1/97/047/008


BeneFIX


Iceland


4.9.2012




EU/1/97/047/008


BeneFIX


Norway


10.10.2012




EU/2/02/033/003-004


Dexdomitor


Iceland


13.9.2012




EU/2/02/033/003-004


Dexdomitor


Norway


30.8.2012




EU/2/02/033/003-004


Dexdomitor


Liechtenstein


31.10.2012




EU/2/07/074/007-009


Prilactone


Liechtenstein


31.12.2012




EU/2/07/078/018-020


Rheumocam


Norway


6.12.2012




EU/2/07/078/018-020


Rheumocam


Liechtenstein


31.12.2012




EU/2/08/090/028


Loxicom


Liechtenstein


31.12.2012




EU/2/10/118/015-021


Activyl


Liechtenstein


31.8.2012




EU/2/11/134/015-017


Inflacam


Iceland


5.9.2012




EU/2/11/134/015-017


Inflacam


Norway


1.11.2012




EU/2/11/134/015-017


Inflacam


Liechtenstein


31.8.2012




EU/2/11/134/018-020


Inflacam


Iceland


6.12.2012




EU/2/11/134/018-020


Inflacam


Liechtenstein


31.12.2012




EU/2/99/015/003-004


Oxyglobin


Liechtenstein


31.12.2012







ANNEX IV
List of withdrawn marketing authorisations
The following marketing authorisations have been withdrawn in the EEA EFTA States during the period 1 July- 31 December 2012:








EU-Number


Product


Country


Date of authorisation




EU/1/00/147/001-012


Hexavac


Iceland


23.7.2012




EU/1/00/147/001-012


Hexavac


Liechtenstein


31.8.2012




EU/1/01/193/001-002


MabCampath


Norway


8.8.2012




EU/1/01/193/001-002


MabCampath


Iceland


30.8.2012




EU/1/01/193/001-002


MabCampath


Liechtenstein


31.8.2012




EU/1/02/205/005-006


Lumigan


Liechtenstein


31.12.2012




EU/1/02/209/001-004


Dynastat


Norway


18.7.2012




EU/1/04/281/001-002, 004


Erbitux


Norway


30.8.2012




EU/1/07/407/001-040


Sprimeo


Iceland


23.7.2012




EU/1/07/407/001-040


Sprimeo


Norway


4.7.2012




EU/1/07/407/001-040


Sprimeo


Liechtenstein


31.8.2012




EU/1/09/513/001-020


Rivastigmine Teva


Norway


10.9.2012




EU/1/09/513/001-020


Rivastigmine Teva


Iceland


20.9.2012




EU/1/09/513/001-020


Rivastigmine Teva


Liechtenstein


31.10.2012




EU/1/09/520/001-020


Exalief


Iceland


6.12.2012




EU/1/09/520/001-020


Exalief


Norway


30.7.2012




EU/1/09/570/001-060


Imprida HCT


Iceland


7.12.2012




EU/1/09/576/040


Irbesartan Teva


Liechtenstein


31.12.2012




EU/1/09/582/001


Rilonacept Regeneron


Iceland


14.11.2012




EU/1/09/582/001


Rilonacept Regeneron


Norway


24.10.2012




EU/1/10/634/005-011


Ribavirin Mylan


Liechtenstein


31.12.2012




EU/1/11/638/001-080


Sprimeo HCT


Liechtenstein


31.8.2012




EU/1/11/669/005


Teysuno


Liechtenstein


31.12.2012




EU/1/11/679/007


Pravafenix


Liechtenstein


31.12.2012




EU/1/11/680/001-080


Riprazo HCT


Norway


30.8.2012




EU/1/11/680/001-080


Riprazo HCT


Iceland


12.9.2012




EU/1/11/683/001-080


Sprimeo HCT


Norway


6.7.2012




EU/1/11/683/001-080


Sprimeo HCT


Iceland


23.7.2012




EU/1/11/691/006-013


Eliquis


Liechtenstein


31.12.2012




EU/1/11/697/013-024


Temozolomide SUN


Liechtenstein


31.12.2012




EU/1/12/765/007-009


Sabervel


Liechtenstein


31.12.2012




EU/1/12/776/017-023


Fycompa


Liechtenstein


31.12.2012




EU/1/12/780/029-034


Jentadueto


Liechtenstein


31.12.2012




EU/1/96/006/008-011


NovoSeven


Liechtenstein


31.12.2012




EU/1/97/040/001-002


Teslascan


Iceland


14.9.2012




EU/1/99/099/001-006


Zerene


Norway


23.8.2012




EU/1/99/099/001-006


Zerene


Iceland


7.9.2012




EU/1/99/099/001-006


Zerene


Liechtenstein


31.10.2012




EU/1/99/101/001


Regranex


Norway


16.7.2012




EU/1/99/101/001


Regranex


Liechtenstein


31.8.2012




EU/1/99/101/001


Regranex


Iceland


14.8.2012




EU/1/99/103/009


Refacto AF


Liechtenstein


31.12.2012







ANNEX V
List of suspended marketing authorisations
The following marketing authorisations have been suspended in the EEA EFTA States during the period 1 July- 31 December 2012:








EU-Number


Product


Country


Date of authorisation




EU/1/09/509/001-004


Ribavirin Teva


Iceland


14.12.2012




EU/1/09/509/001-004


Ribavirin Teva


Norway


6.12.2012




EU/1/09/527/001-016


Ribavirin Teva Pharma BV


Iceland


14.12.2012




EU/1/09/527/001-016


Ribavirin Teva Pharma BV


Norway


6.12.2012